Takeda Ordered to Pay $6 Billion Portion of Punitive Damage Award in Actos Lawsuit
The makers of a diabetes drug allegedly tied to bladder cancer and other side effects are planning to appeal a U.S. federal jury’s decision yesterday to award an Actos lawsuit plaintiff $6 billion in punitive damages, according to Reuters.com.
The $6 billion judgment was part of $9 billion in punitive damages awarded to the plaintiff in the first federal trial of an Actos bladder cancer lawsuit. Eli Lilly & Co. was ordered to pay the remaining $3 billion.
The Plaintiff who filed the Actos lawsuit was also awarded $1.475 million in compensatory damages.
Announced on April 7th in the U.S. District Court, Western District of Louisiana, the diabetes drug case involved allegations that Takeda Pharmaceuticals Co. and Eli Lilly concealed cancer risks in its marketing of Actos. The manufacturer was ordered to pay a portion of the punitive damage award, while its co-defendant, Eli Lilly is liable for the other, according to the Reuters report. A spokesperson for Takeda said that the company plans to “vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal.”
The punitive damage award in this case, which was reportedly met with “stunned silence” in the Lafayette courtroom, exceeded a $5 billion verdict against Exxon Mobil Co. in 1989’s Exxon Valdez oil spill. In 2008, the U.S. Supreme Court ruled that this particular penalty was “excessive” and knocked it down to $500 million.
Decision to Award $9 Billion in Actos Lawsuit a Quick One, Lawyer Says
An Actos lawyer for the plaintiff, whose case alleged new-onset cancer caused by the medication, said the U.S. federal jury deliberated for only an hour and 10 minutes before releasing its decision.
Following news of this verdict, Takeda’s shares dropped by 8.8 percent in Japan—where the pharmaceutical company is based—resulting in an eight-month low in Tokyo trading.
In May 2013, a U.S. judge decided to throw out a $6.5 million damage award against Takeda after the plaintiff’s evidence associating Actos with bladder cancer was found to be insufficient.
Court documents show that thousands more lawsuits against Takeda are moving forward in the U.S. District Court, Western District of Louisiana. A Case List updated on March 13th shows 2,923 claims now filed in the federal multidistrict litigation by plaintiffs who allege the company’s failure to warn about side effects of its product, which was designed defectively. This update was provided by the U.S> Judicial Panel on Multidistrict Litigation (JPML).
Filing an Actos Lawsuit
With more than 2,900 cases now filed in a federal Actos lawsuit litigation, the time is now to file a case of your own. Those who may have developed bladder cancer after taking the diabetes medication are urged to call the Firm today at (877) 779-1414.